Trial Profile

Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use

08 Jun 2022 Status changed from active, no longer recruiting to completed.
14 Sep 2021 Results of subgroup analysis assessing the effects of the immunotherapy era on maintenance outcomes in advanced nonsquamous NSCLC presented at the 2021 World Conference on Lung Cancer
27 Oct 2020 Planned End Date changed from 1 Apr 2018 to 8 May 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com